RxSight, Inc.

RxSight, Inc.

RXST·NASDAQ

$5.10

+4.1%
HealthcareMedical - Devices

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

At a Glance

Live Snapshot
Market Cap$211.12M
EPS-0.9500
P/E Ratio-5.37
Earnings Date08/06/2026

rxst

Cash at End of Period

Last Annual Value

19.95M

3-Year CAGR

17%

5-Year CAGR

7%

10-Year CAGR

8%

RxSight, Inc.

RxSight, Inc. Competitors Analysis of Cash at End of Period

RXST · NASDAQ
CompanyCash at End of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
RXST logo
RxSight, Inc.
NASDAQ:RXST
19.95M
24.2%-4.5%N/A 
21.62M
-13.2%19.1%29.7%
154.50M
3.7%-18.4%N/A
83.45M
11.0%24.2%10.5%
8.95M
-46.2%-24.8%30.6%
21.36M
16.9%-16.0%-0.6%
43.45M
50.7%10.0%25.7%
SRDX logo
Surmodics, Inc.
NASDAQ:SRDX
36.12M
-4.5%3.0%3.8%
10.71M
-6.2%-36.8%N/A
15.65M
51.0%27.2%24.6%
NPCE logo
NeuroPace, Inc.
NASDAQ:NPCE
21.81M
6.3%2.5%N/A
RxSight, Inc.

RxSight, Inc. Fair Value Envelope

RXST · NASDAQ

Our analysis suggests that RXST has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.1, this represents a potential HIDDEN relative to our calculated worth for RxSight, Inc..

Intrinsic Value
Current Price: $5.1